Merck KGaA

Executive Summary

Merck KGaA is a diversified science and technology leader operating across Healthcare, Life Science, and Electronics. In Healthcare, the company focuses on oncology, neurology, and immunology, with key products including Bavencio (avelumab) and Mavenclad (cladribine). The Life Science unit, led by MilliporeSigma, provides critical tools for bioprocessing and research, benefiting from strong demand in biopharma manufacturing. The Electronics segment supplies specialty materials for semiconductors and displays, capitalizing on trends like chip miniaturization and OLED displays. In 2025, the company delivered resilient growth despite macroeconomic headwinds, driven by innovation and strategic partnerships. With a robust pipeline and disciplined capital allocation, Merck KGaA is well-positioned for sustained value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Bavencio for adjuvant treatment of renal cell carcinoma65% success
• Q4 2026Launch of new biosimilar portfolio under the Life Science division80% success
• Q2 2026Strategic partnership or acquisition in semiconductor materials50% success